Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.

@article{Boissinot2012InductionOD,
  title={Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.},
  author={M. Boissinot and M. Inman and Aiden Hempshall and S. R. James and J. Gill and P. Selby and D. Bowen and R. Grigg and P. Cockerill},
  journal={Leukemia research},
  year={2012},
  volume={36 10},
  pages={
          1304-10
        }
}
Histone deacetylase inhibitors (HDACIs) are in advanced clinical development as cancer therapeutic agents. However, first generation HDACIs such as butyrate and valproate are simple short chain aliphatic compounds with moieties resembling acetyl groups, and have a broad spectrum of activity against HDACs. More complex second generation HDACIs undergoing clinical trials, such as the benzamide group compounds MS-275 and MGCD0103, are specific primarily for HDAC1 and HDAC2. To expand the… Expand
Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition
Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes
A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling
...
1
2
3
4
...

References

SHOWING 1-10 OF 31 REFERENCES
Histone deacetylase: a target for antiproliferative and antiprotozoal agents.
...
1
2
3
4
...